Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells

Guo Qiang Chen, Jing Zhang, Qian Zhao

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have been used clinically for effective treatments of patients with acute promyelocytic leukemia (APL, a unique subtype of AML) through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.

Original languageEnglish (US)
Pages (from-to)4094-4101
Number of pages8
JournalChinese Science Bulletin
Volume54
Issue number22
DOIs
StatePublished - Dec 1 2009

Fingerprint

Acute Myeloid Leukemia
Apoptosis
Acute Promyelocytic Leukemia
Hematologic Neoplasms
Tretinoin
Cytogenetics
Cell Differentiation
Therapeutics
Research Personnel
arsenic trioxide

Keywords

  • Apoptosis
  • Cell differentiation
  • Chemical biology
  • Leukemia

ASJC Scopus subject areas

  • General

Cite this

Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells. / Chen, Guo Qiang; Zhang, Jing; Zhao, Qian.

In: Chinese Science Bulletin, Vol. 54, No. 22, 01.12.2009, p. 4094-4101.

Research output: Contribution to journalReview article

@article{bc7b1b42a4144f07a8e3369a03ec8617,
title = "Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have been used clinically for effective treatments of patients with acute promyelocytic leukemia (APL, a unique subtype of AML) through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.",
keywords = "Apoptosis, Cell differentiation, Chemical biology, Leukemia",
author = "Chen, {Guo Qiang} and Jing Zhang and Qian Zhao",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s11434-009-0628-y",
language = "English (US)",
volume = "54",
pages = "4094--4101",
journal = "Science Bulletin",
issn = "2095-9273",
publisher = "Springer Science + Business Media",
number = "22",

}

TY - JOUR

T1 - Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells

AU - Chen, Guo Qiang

AU - Zhang, Jing

AU - Zhao, Qian

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have been used clinically for effective treatments of patients with acute promyelocytic leukemia (APL, a unique subtype of AML) through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.

AB - Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have been used clinically for effective treatments of patients with acute promyelocytic leukemia (APL, a unique subtype of AML) through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.

KW - Apoptosis

KW - Cell differentiation

KW - Chemical biology

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=74549179661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549179661&partnerID=8YFLogxK

U2 - 10.1007/s11434-009-0628-y

DO - 10.1007/s11434-009-0628-y

M3 - Review article

AN - SCOPUS:74549179661

VL - 54

SP - 4094

EP - 4101

JO - Science Bulletin

JF - Science Bulletin

SN - 2095-9273

IS - 22

ER -